MDMia S. DeSimone

Mia S. DeSimone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mia S. DeSimone has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure

    by K. Khaddour, P. Kote, M. Liu, A. Giobbie-Hurder, I. Dryg, A. Goyal, J.P. Guenette, J.D. Schoenfeld, D.N. Margalit, R.B. Tishler, et al.


  • Impact of clinicopathological features on prognosis of thin melanomas: a retrospective cohort analysis

    by Emma Beagles, Sara Khattab, Olivia M Burke, Nga Nguyen, Crystal Chang, Katie Roster, Ahmad Rajeh, Hannah Rashdan, Cameron Moseley, Boshen Yan, et al.

    Using a large multi-institutional cohort of patients with thin melanomas, our study identified that while predictive of improved prognosis in later stage disease, the presence of tumour-infiltrating lymphocytes is associated with poorer outcomes in patients with thin melanomas. Increasing mitotic rate, Charlson Comorbidity Index, absence of radial growth phase and self-pay/no insurance are also significantly associated with poorer outcomes, while tumour thickness, historically one of the most important prognostic features, is not independently associated with recurrence or mortality. This study elucidates novel risk factors that could prognosticate recurrence or mortality among thin melanomas and can be used to enable more personalized surveillance and therapeutic strategies.

  • Multicenter Evaluation of Certainty and Reliability in Calciphylaxis Diagnosis Using a Digital Imaging Platform

    by Soma Jobbagy, Emilio Madrigal, Houda Bouchouari, Tianqi Ouyang, Sagar U. Nigwekar, Rosalynn M. Nazarian, Motunrayo Adisa, Scott Bresler, May Chan, Kristine Chaudet, et al.


  • Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome

    by Emily Hartsough, Mia S DeSimone, Mayra E Lorenzo, Dora Dias-Santagata, Vania Nose, Mai P Hoang

    Cowden syndrome (CS) is a multisystem disease with an elevated lifetime risk of internal malignancy. We aim to assess the role of PTEN immunostain as a screening test for CS in a variety of common CS-associated neoplasms, with a particular focus on cutaneous tumors. We retrospectively searched for patients meeting criteria for CS and/or demonstrating germline PTEN mutation from 2008 to 2022. We then performed PTEN immunostains on tumors of these patients as well as control cases. Our study included 30 patients with CS who had a total of 25 CS-associated malignancies (13 thyroid, 8 breast, and 4 endometrial carcinomas). Specifically, there were 11 patients with biopsy-confirmed CS-associated cutaneous neoplasms, including 1 patient with multiple trichilemmomas and 3 with multiple sclerotic fibromas. In total, 45 CS-associated tumors (6 trichilemmomas, 7 sclerotic fibromas, 5 thyroid carcinomas, 18 adenomatous thyroid nodules, 6 breast carcinomas, and 3 endometrial carcinomas) and 31 non-CS cases (9 trichilemmomas, 5 sclerotic fibromas, 8 adenomatous thyroid nodules, and 3 thyroid, 3 breast, and 3 endometrial carcinomas) were available for PTEN immunohistochemical staining. PTEN expression was lost in 43 (96%) of 45 CS-associated lesions and retained in 30 (97%) of 31 sporadic tumors. The overall sensitivity and specificity of PTEN loss of expression as a screening test for CS were 96% and 97%, respectively. PTEN immunohistochemistry on CS-associated tumors, especially trichilemmomas, can serve as a readily accessible and cost-effective screening test for CS.


  • Lessons learned: A look back at the performance of nine COVID-19 serologic assays and their proposed utility

    by Nicole V. Tolan, Mia S DeSimone, Maria D Fernandes, Joshua E. Lewis, Daimon P Simmons, Peter H Schur, Manfred Brigl, Milenko J Tanasijevic, Michaël Desjardins, Amy C Sherman, et al.


  • Open Access

    Prediction of early-stage melanoma recurrence using clinical and histopathologic features

    by Guihong Wan, Nga Nguyen, Feng Liu, Mia S. DeSimone, Bonnie W. Leung, Ahmad Rajeh, Michael R. Collier, Min Seok Choi, Munachimso Amadife, Kimberly Tang, et al.

    Prognostic analysis for early-stage (stage I/II) melanomas is of paramount importance for customized surveillance and treatment plans. Since immune checkpoint inhibitors have recently been approved for stage IIB and IIC melanomas, prognostic tools to identify patients at high risk of recurrence have become even more critical. This study aims to assess the effectiveness of machine-learning algorithms in predicting melanoma recurrence using clinical and histopathologic features from Electronic Health Records (EHRs). We collected 1720 early-stage melanomas: 1172 from the Mass General Brigham healthcare system (MGB) and 548 from the Dana-Farber Cancer Institute (DFCI). We extracted 36 clinicopathologic features and used them to predict the recurrence risk with supervised machine-learning algorithms. Models were evaluated internally and externally: (1) five-fold cross-validation of the MGB cohort; (2) the MGB cohort for training and the DFCI cohort for testing independently. In the internal and external validations, respectively, we achieved a recurrence classification performance of AUC: 0.845 and 0.812, and a time-to-event prediction performance of time-dependent AUC: 0.853 and 0.820. Breslow tumor thickness and mitotic rate were identified as the most predictive features. Our results suggest that machine-learning algorithms can extract predictive signals from clinicopathologic features for early-stage melanoma recurrence prediction, which will enable the identification of patients that may benefit from adjuvant immunotherapy.


  • Delivering Health Care to Refugee and Immigrant Women in Clarkston, GA: Opening a Women’s Clinic [28M]

    by Jessica Kaplan, Mia M DeSimone, Thien-Linh Ba Phan Le, Sarah Ba Newman, Jennifer Goedken

    INTRODUCTION: Refugee women are a vulnerable population who experience barriers accessing healthcare and disparities in health outcomes. Eighty-five women from the Clarkston Community Health Center (CCHC), a primary care clinic serving an uninsured refugee and immigrant population, were surveyed using a women’s health needs assessment. Eighty-four percent of reproductive aged women experienced unmet family planning needs, 46% of women over 40 years had never had a mammogram, and 29% of women over 21 years had never had a pap smear. While the survey didn’t specifically address sexually transmitted infections (STIs), 38/82 (46%) requested access to STI screening. Lack of knowledge and access to care were cited as common barriers. METHODS: Using the CCHC infrastructure, funding from Emory School of Medicine, and volunteer community providers, we opened a women’s clinic in January 2017. We have collected data on number of patients, presenting complaints, services provided, and referrals. RESULTS: As of September 2017, the clinic has served 230 women. Out of the 185 women offering reasons for attending clinic, 24% presented for contraception, 14% for STI testing or treatment, 10% for Pap smears, 3% for breast complaints, and the other 49% for specific gynecologic complaints. We have performed 80 pap smears, tested or treated 63 women for STI’s, and provided 33 women with contraception. We have referred 46 women for mammograms or other evaluation. CONCLUSION: The needs assessment was critical to the development of the clinic. However, it underestimated the STI related needs of the population. This may be important to others considering a similar undertaking.